Form 4: Apyx Medical Corp Director Stavros G. Vizirgianakis Acquires 17,000 Stock Options

Director Stavros G. Vizirgianakis acquired 17,000 stock options in Apyx Medical Corp on August 8, 2024, as part of the Director Compensation Program.

Summary

• On August 8, 2024, Stavros G. Vizirgianakis, a director of Apyx Medical Corp, acquired 17,000 stock options.
• The options were granted as part of the Issuer's Director Compensation Program.
• The exercise price of the options is $1.02.
• The options vest ratably over a 12-month period and become fully vested and exercisable on the first anniversary of the date of grant.
• The options expire on August 8, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director and shareholder interests. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service by the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a standard practice for compensating directors in publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Director compensation packages often include stock options to align director and shareholder interests.
• Vesting schedules are common to incentivize continued service.
• The specific terms of the option grant (exercise price, vesting schedule, expiration date) are typical for director compensation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with theirs.
• The director benefits from the potential future value of the stock options.

Key Dates